Canadian medical cannabis producer Atlas Biotechnologies has given a $300,000 grant to the University of Alberta for research into cannabis as a therapy for multiple sclerosis (MS), Alzheimer’s disease, and Huntington’s disease,
The Edmonton Journal reports. Throughout the U.S. and Canada, those conditions are already often approved for medical cannabis access but the researchers hope to find scientific proof as to why it works.
“There isn’t solid scientific evidence for most of what people are saying about cannabis,” said Ross Tsuyuki, U of A pharmacology department chair who is supervising the research. “We have the researchers that know these conditions that are possible targets for where cannabis could be beneficial.”
The funding agreement allows researchers full autonomy over how the study is conducted and how the results are used. Anne Taylor, a pharmacology professor at the university, said she hopes the research will limit the use of opioids in pain management for the conditions.
Read the full article at Ganjapreneur